Wissenschaftlich-technischer Beirat

Der wissenschaftlich-technische Beirat berät die Steuerungsgruppe in wissenschaftlichen Fragen. Eine wichtige Aufgabe des Beirats ist es, die Forschungsergebnisse schnell und sicher in die klinische Anwendung zu bringen. Er begutachtet diesbezüglich unsere Forschungsprojekte und prüft, ob wir unsere Forschungsziele einhalten. Außerdem kontrolliert der Beirat regelmäßig den Erfolg unserer wissenschaftlichen Arbeit. 

Der Beirat setzt sich aus externen, international bekannten Persönlichkeiten aus Wissenschaft und Wirtschaft zusammen. Zum Beirat gehören mindestens drei und höchstens elf Mitglieder. Der Beirat informiert die Partner des BCRT (Charité und BIH) schriftlich über die Beratungen.

Lina Badimon; Institute for Cardiovascular Science, Barcelona, Spain

Lina Badimon    

Prof. Lina Badimon is the Director of the Cardiovascular Research Center in Barcelona (CSIC-ICCC) in the Hospital Santa Creu and San Pau, Autonomous University of Barcelona. She is also Lecturer Adjunt Associate Professor of Medicine - Cardiology - at Mount Sinai School of Medicine, New York and Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona.

Her research activities focus on vascular and cardiac pathology. She has published over 380 articles in highly qualified scientific journals with her work highly quoted in the scientific literature (Citations: over 18.100; h-index 59). She has written 230 reviews and book chapters. She is Member of Editorial Boards of various international scientific journals.

Previous appointments include: Fellow at the Division of Cardiovascular Diseases at The Mayo Clinic, Rochester, MN, USA (1981-1983); Director of the Cardiology Basic Research Laboratory of the Division of Cardiology at the Mount Sinai Medical Center, New York, NY (1983-1991); Assistant Professor of Medicine (1983-1987) and Associate Professor of Medicine (1988-1991) at the Mount Sinai School of Medicine, NY; Lecturer in Medicine at Harvard Medical School, Boston (1991-1994); Consultant at the Cardiac Unit, at the Massachusetts General Hospital, Boston (1991-1994). 

Council and scientific appointments: Vice-President of the Spanish Society of Cardiology (2014-2016); Chairman of the Council on Basic Cardiovascular Science (2014-2016) and Chairman of the Working Group on Coronary Pathophysiology and Microcirculation (2012-2014) of the European Society of Cardiology; Past-President of the Spanish Society of Atherosclerosis (1996-2000); Past-President of the European Society for Clinical Investigation (2000-2002); Past-Chairman of the Working Group on Thrombosis of European Society of Cardiology (2002-2004). 

Honorary Appointments: Fellow of the Cardiovascular Science Council and Fellow of the Atherosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association; Fellow of the European Society of Cardiology; Distinguished Fellow of the International Atherosclerosis Society.

Manuela Battaglia; Fondazione Telethon

Manuela Battaglia   


Manuela Battaglia was born in Milan in 1971. She received her PhD from the Medical College of Wisconsin in 2001 (and a second one in 2014 from the University of Utrecht), and eventually returned to Italy as a post-doctoral fellow at the San Raffaele Telethon Institute for Gene Therapy in Milan under the direct supervision of Prof. Maria Grazia Roncarolo. After six years of intensive work in the field of gene therapy, Manuela decided to invest her scientific career in understanding, and possibly finding a definitive solution for, type 1 diabetes. Thus, in 2007 she moved to the San Raffaele Diabetes Research Institute (Milan, Italy) as a group leader, and she was subsequently promoted head of unit (2012). From 2013 to 2019 she was Deputy Director of the San Raffaele Diabetes Research Institute. Since 2019 she is head of research at the Telethon Foundation.

Fascinated by human immunology, and deeply committed to research in this sphere, she believes that access to - and the subsequent study of - precious human samples is key to the advancement of biomedical knowledge. At the same time, she recognizes the power of animal models, and makes constant use of them. 

Manuela’s over-riding target is to understand how the immune system transforms during autoimmunity and how said system can be manipulated to prevent/block immune-mediated diseases. She supervises science on the bench, but her mind’s eyes hovers constantly at the bed-side and ponders how to improve patient benefits. 

Her main goal in Science (and in Life) is to work hard to continuously challenge and (possibly) overcome "dogmas".  





Andrew Carr; University of Oxford

Andrew Carr   

Professor Andrew Carr research interests are primarily focused on developing and evaluating surgical technologies including joint replacement, arthroscopy, minimally invasive surgery and tissue engineering. His research group investigates cellular and molecular mechanisms of soft tissue ageing and failure. He has developed novel woven and electrospun tissue engineering scaffolds for soft tissue repair which are now entering clinical trials. With colleagues in Oxford he pioneered the involvement of patients in assessing the outcome of orthopaedic operations and has invented a series of patient reported outcome measures (PROMS). The Oxford Scores are now used worldwide in clinical trials and by national joint replacement registries.


  •  1982: Graduate, University of Bristol 

Professional History

  • Since 2001: Nuffield Professor of Orthopaedics and Head of Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
  • 2011 - 2013: Divisional Director of Oxford University Hospitals NHS Trust
  • 2001 - 2011: Nonexecutive Director of Nuffield Orthopaedic Centre NHS Trust
  • 2008: Founder Director of the NIHR Musculoskeletal Biomedical Research Unit (BRU), Oxford
  • 2002 - 2008: Directer of the Botnar
  • 2002: Founder of the Botnar Research Centre as an Institute of Musculoskeletal Sciences


Awards & Honors

  •   Robert Jones Gold Medal of the British Orthopaedic Association
  • Hunterian Professorship of the Royal College of Surgeons of England
  • 2009: Fellow of the Academy of Medical Sciences

Stephane Heymans; Masstricht University

Stephane Heymans    

Stephane Heymans is Professor of Cardiomyopathies and Head of the Centre for Heart Failure Research, Department of Cardiology, Maastricht University.
In 2008 he established his independent research laboratory at Cardiovascular Research Institute Maastricht. His research interests focus on the molecular mechanisms of heart failure, looking at the interplay between inflammatory cells, fibroblasts and cardiomyocytes. Particular focus is on the role of non-structural matrix proteins, matrix turnover and non-coding RNAs. 


  • 2000: PhD in Medical Sciences, studying the role of proteinases in acute myocardial infarction
  • 1995: Medical Degree from the KULeuven, Belgium

Professional History

  • 2008: He established his independent research laboratory at Cardiovascular Research Institute Maastricht
  • 2006: He took over the Multidisciplinary Cardiomyopathy Program (Genetics, Immunology, Microbiology and Pathology departments)
  • 2003: He joined the Cardiology Department University Hospital of Maastricht as an academic medical specialist


  • Chair of the Strategic Board of the Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Professor of “Inflammation and Matrix Biology in Cardiomyopathies” at the University of Leuven
  • Board member of the ESC Heart Failure Association, ESC Working Group of Myocardial Function, ESC Heart Failure Association Committee on Diastolic Heart Failure and ESC Heart Failure Association Committee on Translational Research

Roland Lauster; Technische Universität Berlin + BSRT, Berlin

Roland Lauster   

Medical Biotechnology

Rheumatic diseases are generally characterized by a progressing tissue degeneration process. This concerns in the first line cartilage destruction of the joints but also holds true for soft tissues like skin or kidney in systemic arthritis. Future perspectives in the treatment are therefore not limited in controlling the inflammation but also include strategies in tissue regeneration. In order to do so, autologous or allogenic stem cell therapies offer a broad range of possible applications. In all cases, however an intact microenvironment for cell differentiation is required. The focus of the molecular biology group is the analysis of such cell differentiating environments in some selected organ structures. We focus on growth and growth-differentiation factors from the TGF-ß and the FGF families, their antagonists, modifying enzymes, oxygen supply and mechanical load on the differentiation of chondrocytes. The second focus is the characterization of stem cells in the human hair follicle. This organ provides insights into general mechanisms of organogenesis and the organisation of stem cell niches. In addition, organ cultures can be used for drug screening and tissue repair.



Andrew Pitsillides; The Royal Veterinary College

Andrew Pitsillides    

Research Group: Musculoskeletal Biology

Research Centre: MicroCT

Professor of Skeletal Dynamics. His research explores skeletal mechanobiology across diverse biological settings; from the role of embryo movement in the emergence of skeletal form, to how bones and joints respond to functional/ traumatic load in growth, adulthood and ageing.

Research: Andrew's work straddles many inter-related themes in skeletal biology focussed on bone and joint mechanobiology.

Studies on the role of early embryo movement in synovial joint development and in acquisition of skeletal proportions are among the first to show that local mechanomodulatory infuences on cell: extracellular matrix interactions were pivotal in the emergence of skeletal form and growth. His group’s in vitro studies described how limb movements might directly influence cell behaviour to achieve joint cavitation, essential for articulation, establishing key roles for ERK/p38 kinases and factors otherwise 'classically' linked to inflammatory pathways. His group are now exploring how mechanobiology may regulate endochondral ossification processes, with a specific focus on identifying key targets for translation.

Work in his group also aims to define how developing and adult bone adapts to functional use. His work found that nitric oxide production was an early obligatory step in such mechanomodulation, with a genetic component linked to growth rate. His work also contributed to defining important differences between how osteocytes and osteoblasts might contribute to bone mechanoadaptive responses and how these fail in osteoporosis. His group have recently developed an elegant in vivo model for addressing these questions by controlled in vivo bone loading and is using state-of-the-art imaging to explore how bone shape and mass are biomechanically matched to function. Additionally, his group's new focus on the joint's osteochondral unit is a merging of much previous research.

H-Index: 46, Citation: 6626 (05/2020 Google Scholar)


Ronenn Roubenoff; Novartis Institutes of Biomedical Research

Ronenn Roubenoff  

Vice president and since 2010 global translational medicicne head of musculskeletal diseases at the Novartis Insitute for Biomedical Research.

Specialties: Translational medicine, Rheumatology, Nutrition, Epidemiology, Drug Development, Sarcopenia, Aging

Dr. Roubenoff has done pioneering work on the interactions of nutrition, exercise and hormonal and immune regulators of metabolism in aging and chronic disease, including rheumatoid arthritis, osteoarthritis, and HIV infection. He is an internationally recognized authority on sarcopenia, translational medicine, and the use of biomarkers in drug development. He has published over 250 papers in the medical literature as well as writing for lay audiences. He is co-author of a New York Times Bestselling book on exercise and nutrition treatment of arthritis. Dr. Roubenoff has served on many NIH study sections, WHO committees, American Society for Nutrition Committees, Animal Care and Use and Institutional Review Committees, and as a reviewer for journals, foundations, and charities.

 H-Index: 98, Citation: 36023 (05/2020 Goggle Scholar)







Molly Stevens; Imperial College London

Molly Stevens


Molly Stevens is currently Professor of Biomedical Materials and Regenerative Medicine and the Research Director for Biomedical Material Sciences in the Institute of Biomedical Engineering at Imperial College. n 2010 she was recognised by The Times as one of the top ten scientists under the age of 40 and also received the Polymer International-IUPAC award for creativity in polymer science, the Rosenhain medal and the Norman Heatley Prize for Interdisciplinary research from the Royal Society of Chemistry. In 2009 she was awarded the Jean Leray Award from the European Society for Biomaterials, in 2007 the prestigious Conference Science Medal from the Royal Pharmaceutical Society and in 2005 the Philip Leverhulme Prize for Engineering. She has also recently been recognised by the TR100, a compilation of the top innovators, under the age of 35, who are transforming technology - and the world with their work. Her previous awards include the Ronald Belcher Memorial Lecture Award from the Royal Society of Chemistry (2000) and both the Janssen Prize and the UpJohn Prize for academic excellence and research. In 2010 Molly was awarded the RSC Norman Heatley Prize and the IOM3 Rosenhain Medal and Prize, In 2012 Molly was awarded the Griffith Prize and medal from IOM3.  In 2012 she presented the Royal Society Clifford Patterson Lecture and in 2013 she was elected Fellow of the Royal Academy of Engineering.



Andre Terzic; Mayo Clinic, Minnesota

Andre Terzic

Focus areas: Regenerative medicine and stem cell biology, Cardioprotection, Heart failure, Genetics of cardiac disease and stress tolerance, Bioenergetic signaling, nucleocytoplasmic communication and ion channel biology

Andre Terzic, M.D., Ph.D., has pioneered regenerative medicine at Mayo Clinic. He has authored more than 450 publications, advancing diagnostic and therapeutic strategies for heart failure. His works include team-science efforts in the discovery of genes for dilated cardiomyopathy and atrial fibrillation. He led efforts in the development of next-generation regenerative solutions, including first-in-class products for heart repair. His scientific manuscripts have been cited more than 10,000 times.

Dr. Terzic is Michael S. and Mary Sue Shannon Director, Mayo Clinic Center for Regenerative Medicine, and Marriott Family Professor in Cardiovascular Diseases Research. He is professor of medicine and pharmacology; chair, Discovery-Translation Advisory Board; director, Marriott Heart Disease Research Program; director, National Institutes of Health Cardiovasology Program; and serves on the board of directors, Mayo Collaborative Services.